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Abstract 9 
Actin-crosslinking proteins assemble actin filaments into higher-order structures essential 10 
for orchestrating cell shape, adhesion and motility. Missense mutations in the tandem 11 
calponin homology (CH) domains of their actin-binding domains (ABDs) underlie numerous 12 
genetic diseases, but a molecular understanding of these pathologies is hampered by the lack 13 
of high-resolution structures of any actin-crosslinking protein bound to F-actin. Here, taking 14 
advantage of a high-affinity, disease-associated mutant of the human filamin A (FLNa) ABD, 15 
we combine cryo-electron microscopy and functional studies to reveal at near-atomic 16 
resolution how the first CH domain (CH1) and residues immediately N-terminal to it engage 17 
actin. We further show that reorientation of CH2 relative to CH1 is required to avoid clashes 18 
with actin and to expose F-actin-binding residues on CH1. Our data explain localization of 19 
disease-associated loss-of-function mutations to FLNaCH1 and gain-of-function mutations 20 
to the regulatory FLNaCH2. Sequence conservation argues that this provides a general 21 
model for ABD-F-actin binding. 22 
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Actin crosslinking proteins mediate assembly of actin filaments into higher-order structures, such 23 
as bundles and orthogonal networks, that play essential roles in determining cell morphology and 24 
behavior1,2. Defects in the actin cytoskeleton underlie numerous genetic diseases, and can arise 25 
from missense mutations in the actin-binding domains (ABDs) of these crosslinking proteins3–5. 26 
Crystal structures of isolated ABDs have shown that they are composed of tandem calponin 27 
homology (CH) domains4–7 but a complete molecular understanding of actin-binding or its 28 
perturbation in disease has been hampered by the lack of a high-resolution structure of any actin-29 
crosslinking protein bound to F-actin.  30 
 31 
Prior to publication of the first ABD crystal structures, three ABD actin-binding sites (ABS1, 32 
ABS2 and ABS3) were predicted based on peptide and fragment binding studies and mutagenesis 33 
of a variety of ABDs8–13. However, their precise boundaries and relative contributions to F-actin 34 
binding were controversial and ABD crystal structures subsequently revealed that the three 35 
putative ABSs do not form a continuous surface and include many buried residues4,7,14. Indeed, 36 
ABS1, which lies in the first helix of CH1, is largely buried at the interface between CH1 and CH2 37 
in the “closed” conformation of the ABD observed in most crystal structures14–16. This, together 38 
with biophysical experiments and electron microscopy studies of ABDs bound to F-actin17–22, led 39 
to models where inter-domain rearrangement opens the tandem CH domains, exposing CH1 40 
domain actin-binding sites and removing steric clashes between CH2 and actin that would prevent 41 
binding. The conformational equilibrium between “closed” and “open” states would thus 42 
determine ABD binding to F-actin but the identity of the actin-binding residues and the nature of 43 
the conformational changes remained to be determined.  44 
 45 
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The essential actin-crosslinking protein filamin A (FLNa) is composed of an N-terminal ABD 46 
followed by 24 immunoglobulin-like domains, the last of which mediates homodimerization23. In 47 
addition to crosslinking F-actin, FLNa binds numerous scaffolding, signaling, and transmembrane 48 
proteins, and so plays vital roles in the regulation of cell morphology, adhesion, migration, 49 
differentiation, and mechanical force-sensing24,25. Consistent with these essential roles, nonsense 50 
or frameshift mutations in the gene for FLNa, which is on the X chromosome, are typically 51 
embryonically lethal in males3,26. In heterozygous females, null FLNa mutations cause 52 
periventricular nodular heterotopia (PVNH), a neuronal differentiation or migration disorder often 53 
also associated with cardiovascular abnormalities27,28. Notably, PVNH can also be caused by rare 54 
missense mutations that cluster in the FLNaCH1 domain, suggesting that these point mutations 55 
result in a loss of function, possibly by disrupting F-actin binding, but this has not been 56 
experimentally tested27,29. In contrast, missense point mutations in the FLNaCH2 domain are 57 
linked to developmental malformations associated with otopalatodigital syndrome spectrum 58 
disorders (OPDSD). Unlike PVNH mutations, OPDSD mutations are believed to confer a gain-of-59 
function effect on FLNa7,30,31 and in the case of the E254K mutation increased affinity for F-actin 60 
has been reported7. Here, we employed cryo-electron microscopy and biochemical and cellular 61 
assays to investigate and characterize the mechanism of ABD binding to F-actin and to rationalize 62 
FLNa human disease mutations in molecular detail. 63 
 64 
Results 65 
A high-affinity FLNaABD mutant reveals the actin-binding interface at near-atomic 66 
resolution 67 
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To understand FLNaABD binding to F-actin and potentially explain the molecular basis of disease 68 
mutations, we used cryo-electron microscopy (cryo-EM) to visualize the complex between F-actin 69 
and a FLNaABD construct encompassing the N-terminal 42 residues plus the tandem CH domains. 70 
In initial experiments with wild-type (wt) FLNaABD and phalloidin-stabilized F-actin on an FEI 71 
F20 Tecnai electron microscope we were only able to reproduce low-resolution structures similar 72 
to those seen in other ABD-F-actin structures and only the CH1 domain was evident19,22 (Table 1, 73 
Supplementary Fig. 1a, b). In an attempt to improve ABD decoration of actin filaments and 74 
increase resolution, we performed experiments using FLNaABDs containing OPDSD-associated 75 
gain-of-function point mutations in FLNaCH27. This yielded 6.6 Å and 7.4 Å resolution maps for 76 
the Q170P and E254K mutants respectively (Table 1, Supplementary Fig. 1a, c, d). Notably, the 77 
FLNaABD-E254K map included density for the CH2 domain, albeit at lower resolution 78 
(Supplementary Fig. 1d). We therefore used a Titan Krios electron microscope to image 79 
FLNaABD-E254K in complex with F-actin, allowing us to approach atomic resolution, resolving 80 
both the CH1 domain and F-actin to 3.6 Å resolution (Fig. 1a, Supplementary Fig. 1a). The CH2 81 
domain was also visible but again was at lower resolution and is described further in later sections. 82 
The F-actin structure in the complex is indistinguishable from previously reported structures of 83 
phalloidin-stabilized F-actin (PDB 6C1D, root mean square deviation [RMSD] of Cα atoms in 84 
residues T5-C374 is 0.713 Å)32.  85 
 86 
Until now, mapping actin-binding sites (ABS) in ABDs has been contentious; three putative sites 87 
(ABS1, 2 and 3) have been proposed but there has been a lack of consensus on the boundaries of 88 
these sites and crystallographic data have been unable to reconcile these sites with a continuous 89 
binding surface4,7. Contrary to prior predictions, our structure reveals that neither the proposed 90 
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ABS1 (coarsely mapped to residues 46-56) in helix-A of CH1 nor ABS3 (residues 163-181) in 91 
helix-A of the CH2 domain directly engages F-actin. Instead, the ABD binds F-actin through a 92 
short sequence immediately N-terminal to the CH1 domain (residues L35-K42) which we term 93 
ABS-N, as well as the predicted ABS2 (residues V122-W142) and structurally adjacent residues 94 
R91-L104 which were not previously implicated in F-actin binding and which we term ABS2’ 95 
(Fig. 1b). These sites mediate ABD binding in the groove between subdomains 1 and 2 on one 96 
actin monomer (n) (1348 Å2 of buried surface area) and subdomain 1 on the adjacent (n+2) 97 
monomer (burying 505 Å2) (Fig. 1b). 98 
 99 
FLNa residues immediately N-terminal to CH1 contribute to F-actin binding. 100 
Although most of the actin-bound FLNaCH1 domain in our cryo-EM structure closely resembles 101 
that of the unbound FLNaABD-E254K crystal structure (PDB 3HOC, RMSD of Cα atoms in 102 
residues A39-S149 is 1.094 Å) the first turn of helix-A rearranges to engage F-actin and we can 103 
resolve additional N-terminal residues 29-38 which were largely disordered in prior FLNa X-ray 104 
structures6,7 (Fig. 2a,b). To test the importance of this region in F-actin binding, we generated a 105 
series of N-terminal truncations of C-terminally GFP-tagged FLNaABD constructs (FLNaABD-106 
GFP) and assessed co-localization with F-actin in transfected NIH-3T3 fibroblasts. Briefly, GFP 107 
targeting to actin stress fibers was assessed in each GFP-positive cell by a sample-blind observer 108 
using an actin targeting score ranging from 1 (no targeting) to 7 (strong targeting); additionally, 109 
overall co-localization of GFP and F-actin signals within cells was assessed by calculation of 110 
Pearson’s Correlation Coefficient (see Methods). Both methods indicated that, whereas loss of 111 
amino acids 1-27 or 1-32 had no impact on F-actin co-localization, loss of 1-37 or 1-40 partially 112 
inhibited co-localization and loss of 1-44 abrogated it (Fig. 2c,d Supplementary Fig. 2a,b) – 113 
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implicating residues 33-44, encompassing ABS-N, in F-actin binding. Immunoblotting of cell 114 
lysates confirmed that all FLNaABD-GFP constructs were expressed at their expected molecular 115 
weights (Supplementary Fig. 2b). Of these N-terminal residues, only 37-44 are visible in 116 
FLNaABD X-ray crystal structures6,7, forming the N-terminus of the first α helix (helix-A). In the 117 
actin-bound conformation, the N-terminus of helix-A is deformed, moving up to ~3Å (Fig. 2b) to 118 
engage actin via a probable cation-π interaction between W41 (conserved in the ABD of all 119 
filamins and α-actinins, Supplementary Note) and actin R28, potentially buttressed by additional 120 
interactions with actin F21 and R95 (Fig. 2e,f). Mutating W41 inhibited FLNaABD targeting to 121 
F-actin in cells (Fig. 2g,h, Supplementary Fig. 2c,d), further supporting the importance of this 122 
region in actin binding. Moreover, we previously reported that a double K42R,K43R mutation in 123 
FLNa helix-A inhibits actin binding33 and our structure shows that K42 may help stabilize ABS-124 
N (Fig. 2f) . Residues N-terminal to helix-A also contribute to actin binding and the importance 125 
of hydrophobic contacts between L35 and actin as seen in our structure is supported by the strongly 126 
impaired F-actin targeting of an L35A mutant (Fig. 2g,h, Supplementary Fig. 2c,d). Together 127 
our structural and functional studies firmly establish the biological relevance of ABS-N in ABD-128 
actin binding. Furthermore, despite low sequence conservation of this region, recent biochemical 129 
studies on utrophin34 and a lower-resolution cryo-EM structure of the actin-bound β-III-spectrin 130 
ABD22 indicate a general role of the ABD N-terminus in actin binding. 131 
 132 
ABS2’ and ABS2 facilitate binding in the groove between adjacent actin subunits  133 
Beyond the ABS-N site, the remaining ABD interface with actin is mediated by ABS2 and ABS2’. 134 
ABS2’ extends from the middle of the C-E loop into the N-terminus of helix-E and engages both 135 
subdomain 2 of the primary interacting actin subunit(n) and subdomain 1 of the adjacent 136 
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actin(n+2) – mainly via hydrophobic and H-bonded interactions (Fig. 3a). We validated the 137 
importance of these interactions by mutating R91, which is well positioned to form an H-bond 138 
with T351 in actin(n+2), F99 which contacts I345 in actin (n+2), and L104 which is stabilized by 139 
CH1-V130 to make a hydrophobic contact with M47 in actin(n). R91E, F99A, and L104A 140 
mutations each inhibited binding in the cellular F-actin targeting assay (Fig. 3b,c, Supplementary 141 
Fig. 3a). 142 
 143 
ABS2 encompasses part of the E-F loop, the short helix-F and the N-terminal half of helix-G, and 144 
engages actin(n) subdomains 1 and 2 (Fig. 3d). We previously reported that a K135R substitution 145 
in ABS2 strongly inhibits actin binding33 and now show that the K135A mutation has a similar 146 
effect (Fig. 3e,f, Supplementary Fig. 3b). K135 is highly conserved across all ABDs 147 
(Supplementary Note) and its sidechain density is directly resolved, indicating potential ionic 148 
interactions with actin E93 and D56 (Fig. 3d). The importance of ABS2 is further supported by 149 
the strong inhibition of F-actin targeting of a charge-reversing lysine mutation at D125, which 150 
forms an ionic bond with K61 and potentially H-bonds with Y53 on actin (Fig. 3d-f, 151 
Supplementary Fig. 3b).  152 
 153 
FLNaABD-E254K binds F-actin in an open conformation  154 
Further examination of our structure reveals the necessity for significant CH2 domain reorientation 155 
to prevent steric clashes with F-actin upon ABD binding. In our wild-type and OPDSD mutant 156 
Q170P structures (Supplementary Fig. 1a-c), as well as other published lower-resolution 157 
structures18,19,22, density for the CH2 domain was not evident, consistent with CH2 domain motion 158 
in the F-actin-bound form. In contrast, in both our F20 and Krios E254K structures the CH2 159 
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domain is apparent, albeit with weaker cryo-EM density and at lower resolution than the rest of 160 
the map (Fig. 4a, Supplementary Fig. 1d). The lower resolution of this domain again indicates 161 
its mobility but was sufficient to reveal that it is oriented outwards and away from actin. 162 
Comparison of our actin-bound FLNaABD-E254K structure with the closed conformation seen in 163 
the FLNaABD-E254K crystal structure7 indicates that the closed conformation is incompatible 164 
with F-actin binding. As reported previously for α-actinin19, superposition of the CH1 domains in 165 
the actin-bound crystal structures reveals that, in the closed conformation, CH2 would clash with 166 
F-actin (Fig. 4b). We therefore conclude that an outward movement of the CH2 domain facilitates 167 
CH1-mediated binding to actin (Fig. 4c). Consistent with this model, isolated FLNaCH1-GFP 168 
strongly targeted to F-actin33 while FLNaCH2-GFP showed no targeting, even with OPDSD 169 
mutations Q170P or E254K which otherwise promoted ABD targeting (Fig. 4d,e, Supplementary 170 
Fig. 4a,b). 171 
 172 
In addition to avoiding steric clashes with actin, our structure reveals that CH2 reorientation also 173 
exposes a previously-unrecognized and highly-conserved actin-binding residue (W142) at the C-174 
terminus of ABS2. Notably, in unbound FLNaABD crystal structures W142 interacts with H255 175 
in CH2, possibly ‘latching’ the ABD in a closed conformation (Fig. 5a). In contrast, in our actin-176 
bound structure, this interaction is replaced by hydrophobic contacts between W142 and actin (Fig. 177 
5b), and a W142A mutation inhibited targeting to F-actin in cells (Fig. 5c,d, Supplementary Fig. 178 
4c). These data argue that W142 plays a regulatory role by binding either CH2 in a closed 179 
inhibitory state, or F-actin in the open active conformation. In α-actinin-4, the homologous W147 180 
may serve a similar role by engaging K255 in CH2. Consistent with this, K255 mutations that 181 
presumably unlatch the ABD and increase affinity for F-actin are associated with the kidney 182 
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disease focal segmental glomerulosclerosis35. Indeed, disease-associated gain-of-function 183 
mutations are found throughout the CH2 domain of FLNa and other ABDs including in its 184 
hydrophobic core (Supplementary Note). Purified OPDSD-associated mutant FLNaABDs 185 
(Q170P or E254K) analyzed by scanning fluorimetry exhibited sharp melting points at lower 186 
temperatures than wild-type FLNaABD, indicative of altered stability (Fig. 5e). Consistent with 187 
their enhanced F-actin targeting (Fig. 4d,e, Supplementary Fig. 4a,b), OPDSD-associated ABD 188 
mutants also displayed increased affinity for F-actin in co-sedimentation assays (Fig. 5f,g, 189 
Supplementary Fig. 4d). We hypothesize that OPDSD mutations destabilize the CH2 domain in 190 
the closed ABD position and shift the conformational equilibrium in favor of ABD opening, 191 
facilitating CH1-mediated F-actin binding. 192 
 193 
Filamin A CH1 domain disease mutations confer loss of function 194 
In addition to the gain-of-function CH2 domain mutations that cause OPDSD, mutations in FLNa 195 
are also linked to the neuronal migration disorder PVNH27. Most FLNa PVNH mutations are 196 
nonsense and frameshift resulting in the loss of FLNa protein3,27. However, rare PVNH-associated 197 
missense mutations that cluster in the FLNaCH1 domain are also seen, and result in phenotypically 198 
similar, albeit somewhat milder, disease27. We propose that these mutations, many of which are 199 
found in the ABS-N, ABS2 and ABS2’ (Supplementary Note), disrupt the actin-binding interface 200 
and cause a loss-of-function. Consistent with this, the PVNH mutations A39G and A128V strongly 201 
impaired FLNaABD targeting to F-actin in cells (Fig. 6a,b, Supplementary Fig. 5a) and F-actin 202 
binding in in vitro co-sedimentation assays (Fig. 6c,d, Supplementary Fig. 4d). Our ability to 203 
purify soluble recombinant FLNaABD mutants with size-exclusion chromatography profiles 204 
consistent with monomeric protein (Supplementary Fig. 5b) argues that the mutations do not 205 
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result in general misfolding. This conclusion is supported by their sharp melting points in 206 
differential scanning fluorimetry experiments (Fig. 6e). Notably, despite a wild-type melting point 207 
and elution profile (Fig 6e, Supplementary Fig. 5b), indicating that FLNaABD A39G is properly 208 
folded, it does not appear to bind actin with the 1:1 ratio seen for the wild-type and other gain- and 209 
loss-of-function mutations (Fig 6c, Supplementary Fig. 4d). This suggests an anomalous binding 210 
mechanism. We propose that A39 (in ABS-N) normally stabilizes the actin-binding residue W41 211 
(Fig. 2e,f). While loss of this stabilization is likely to account for the observed reduction in binding 212 
affinity, it is difficult to envisage how it also alters stoichiometry of binding, either by occluding 213 
adjacent binding sites or by altering F-actin conformation. As this low-occupancy low-affinity 214 
interaction is not conducive to structural analysis we cannot currently explain the reduced 215 
stoichiometry of FLNaABD A39G. For a second PVNH mutation, A128V, we note that A128 216 
does not make direct contact with F-actin but packs tightly behind the main interacting surface of 217 
ABS2 (helix-F). An A128V substitution would perturb this surface (Supplementary Fig. 5c), 218 
likely explaining its disruption of actin binding and possibly contributing to the decrease in thermal 219 
stability seen in scanning fluorimetry experiments (Fig. 6e). Our structure also allows us to 220 
rationalize the previously unexplained M102V PVNH-associated mutation which lies in ABS2’ 221 
and inhibited F-actin binding in cells (Fig. 6a,b, Supplementary Fig. 5a). M102, in conjunction 222 
with F99, extends towards I345 of actin(n+2) (Fig. 3a) and substitution with the shorter valine 223 
likely prevents this interaction. Two other PVNH-associated FLNa mutations that lie outside the 224 
actin-binding interface (E82V and S149F) had little or no effect on F-actin targeting, producing 225 
only modestly reduced actin-targeting scores but no reduction in Pearson’s correlation coefficient 226 
(Fig. 6a,b, Supplementary Fig. 5a,d), and the basis for their clinical effects remains unclear. 227 
Additional FLNaCH1 domain PVNH mutations also occur in ABS2. The V122 side chain is 228 
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wedged between H87 and H88 of actin(n) and a V122G mutation strongly inhibited association 229 
with F-actin (Fig. 6a,b, Supplementary Fig. 5a). The K127N severely inhibited actin targeting, 230 
and in our structure K127 is in range to make an ionic bond with E167 in actin(n+2) (Fig. 6a,b, 231 
Supplementary Fig 5a). Notably, disease-associated mutations in the ABD of FLNc and α-232 
actinin-2 also localize to regions corresponding to FLNa ABS236,37 (Supplementary Note). 233 
Mutations at I119 inhibited F-actin binding (Fig. 6a,b, Supplementary Fig. 5a), probably due to 234 
disruption of the hydrophobic core of CH1, and α-actinin-1 and -2 also contain disease-associated 235 
mutations in this region38,39.  236 
 237 
Discussion  238 
Our high-resolution cryo-EM structure of FLNaABD-E254K bound to F-actin provides a detailed 239 
foundation for understanding the molecular basis of actin binding by tandem CH domains, 240 
revealing several new features of the ABD-actin binding mechanism. We show that upon actin 241 
binding, FLNa residues immediately N-terminal to the CH1 domain become ordered and 242 
contribute to F-actin binding. By identifying three actin-binding sites (ABS-N, ABS2’ and ABS2) 243 
we resolve controversy surrounding the specific sites involved in F-actin binding. We find that 244 
ABS-N participates in hydrophobic and potential cation-π interactions with subdomain 1 of actin 245 
while ABS2’ binds an adjacent F-actin subunit. The previously mapped ABS2 also makes key 246 
ionic and hydrophobic interactions. The functional importance of each of these sites was validated 247 
using structure-guided mutations. Our structure also indicates CH2 domain movement associated 248 
with actin-binding, establishing that, as previously proposed based on earlier lower-resolution 249 
structures18,19,22, binding involves ABD opening and does not involve direct CH2-actin 250 
interactions. In addition to avoiding steric clashes of the CH2 domain with actin, ABD opening 251 
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exposes the highly-conserved actin-binding residue W142 in ABS2 which, in the closed 252 
conformation, binds the CH2 domain, serving as a regulatory latch to stabilize the closed ABD. 253 
Finally, combining cellular and biochemical analysis of disease-associated FLNaABD mutations 254 
with our structural studies helps explain the localization of PVNH disease-associated loss-of-255 
function point mutations to the actin-binding CH1 domain and gain-of-function OPDSD mutations 256 
to the regulatory CH2 domain. 257 
 258 
The N-terminal flanking regions of ABDs are diverse in length and sequence, but the ABS-N 259 
sequence is conserved in filamins and α-actinins (Supplementary Note) and, despite relatively 260 
low sequence similarity with the FLNa N-terminus, deletion of residues 1-27 in utrophin ABD or 261 
1-51 in β-III-spectrin ABD has been shown to dramatically reduce F-actin binding22,34. Thus, 262 
residues N-terminal to CH1 have functionally conserved biological significance in multiple ABDs.  263 
 264 
Notably, at least in the case of FLNa, residues preceding ABS-N are not necessary for actin binding 265 
as N-terminal truncations (Δ1-27 and Δ1-32) did not diminish ABD co-localization with F-actin. 266 
Consistent with this, an alternate FLNa transcript that results in initiation at M28 (equivalent to 267 
our Δ1-27 ABD) produces functional FLNa protein that targets to F-actin40. Furthermore, FLNb 268 
also has a relatively short N-terminus (equivalent to the Δ1-27 FLNaABD) and the FLNbABD 269 
binds F-actin with affinities comparable to the FLNaABD in the present study41. This suggests that 270 
the variability in sequence N-terminal to ABS-N may provide mechanisms to regulate ABD 271 
binding to actin. Indeed, calmodulin binding to N-terminal residues of plectin has been proposed 272 
to regulate plectin interactions with F-actin42,43. Calmodulin has also been reported to inhibit FLNa 273 
binding to F-actin44 but, rather than binding the N-terminal region, calmodulin was proposed to 274 
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utilize a cryptic binding site (residues 87-96) in the FLNaCH1 domain that became exposed upon 275 
F-actin binding. We now show that the proposed calmodulin-binding site faces away from F-actin 276 
and we observe no substantial conformational changes in this site upon F-actin binding, making it 277 
unclear how calmodulin would selectively bind this region in the FLNaABD-F-actin complex to 278 
drive dissociation. Furthermore, despite the strong sequence and structural conservation between 279 
FLNa and FLNb, calmodulin did not inhibit FLNb binding to F-actin41. The structural basis for 280 
any effect of calmodulin on FLNa binding to F-actin therefore remains to be determined. 281 
 282 
FLNa binding to F-actin is however clearly influenced by the CH2 domain and our structural data 283 
show that when bound to F-actin the FLNaABD domain adopts an “open” position distinct from 284 
the closed conformations seen in FLNaABD crystal structures6,7. However, even in the F-actin-285 
bound FLNaABD E254K structure, the lower resolution of the CH2 domain reveals that this 286 
domain is mobile and this presumably explains why it was not visible in most other ABD-actin 287 
complexes19,22. An open conformation is necessary to avoid steric clashes with actin and to expose 288 
the otherwise occupied F-actin binding residue W142 in ABS2. Notably, W142 plays alternative 289 
functional roles by either binding F-actin when the ABD is in an open conformation or binding 290 
CH2 in the closed unbound conformation. W142 is completely conserved across ABDs 291 
(Supplementary Note) and has been implicated in latching α-actinin-435 and plectin45 closed, 292 
indicating that this switching mechanism may be conserved mechanism for controlling the 293 
conformational equilibrium of many, if not all, tandem CH ABDs.  294 
 295 
Our cellular and biochemical studies demonstrate loss-of-actin binding with most of the human 296 
PVNH mutations that localize to FLNaCH1. While some appear to disrupt direct molecular 297 
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interactions with F-actin (M102V, V122G, K127N), others likely elicit their effects by deforming 298 
actin-binding sites or the CH1 domain in general (A39G, I119D, A128V). Conversely, we propose 299 
that the FLNaABD exists in a conformational equilibrium in solution and that the gain-of-function 300 
OPDSD mutations in the CH2 domain exert their effects by shifting that equilibrium towards open 301 
states. The decreased melting temperature and increased affinity of FLNaABD-E254K and -302 
Q170P for F-actin (this report and 7) are consistent with this model but solution dynamics 303 
experiments, as recently applied to the β-III-spectrin ABD22, will be required to test it further. 304 
Notably, the FLNaABD is apparently also dynamic even when bound to F-actin, and this motility 305 
presumably accounts for the lower resolution (or lack of resolution) of the CH2 domain in actin-306 
bound structures19,22, and suggests that there may be many “open” conformations compatible with 307 
actin binding.  308 
 309 
In conclusion, our work provides structural and functional insight into the ramifications of FLNa 310 
disease mutations and resolves substantial controversies in mapping the actin-binding sites of 311 
tandem CH domains.  312 
 313 
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following accession numbers: F20-F-actin-FLNaABD 7833, F20-F-actin-FLNaABD-Q170P 316 
7832, F20-F-actin-FLNaABD-E254K 8918, and Krios-F-actin-FLNaABD-E254K 7831. The 317 
corresponding FLNaABD-E254K filament model was deposited in the Protein Data Bank with 318 
accession number 6D8C. 319 
 320 
15 
 
Acknowledgements 321 
We thank Z. Razinia for generating numerous FLNa constructs, S. Wu for expertise in using the 322 
Krios microscope, J. Lees for advice on model refinement, and M. Lemmon for helpful comments 323 
in preparing the manuscript. We also thank the Yale Center for Research Computing for guidance 324 
and use of the Farnam Cluster, as well as the staff at the YMS Center for Molecular Imaging for 325 
the use of the EM Core Facility. This work was funded by grants from the National Institutes of 326 
Health [R01-GM068600 (D.A.C.), R01-NS093704 (D.A.C.), R37-GM057247 (C.V.S.), R01-327 
GM110530 (C.V.S.), T32-GM007324, T32-GM008283] and an award from American Heart 328 
Association 15PRE25700119 (D.V.I).  329 
 330 
Author Contributions 331 
D.V.I., M.B., and D.A.C. conceived the project. D.V.I., B.S., C.H.C., and M.B. designed 332 
constructs and collected and interpreted biochemical and cellular data. A.H. and D.V.I. prepared 333 
cryo-EM samples and collected cryo-EM data. A.H. and C.V.S. performed cryo-EM analysis and 334 
model refinement. D.V.I, A.H., C.V.S., and D.A.C. wrote the manuscript with contributions from 335 
all other authors.  336 
 337 
Competing Financial Interests Statement 338 
The authors declare no competing interests. 339 
340 
16 
 
References  341 
1. Pollard, T. D. Actin and Actin-Binding Proteins. Cold Spring Harb. Perspect. Biol. 8, 575–591 342 
(2016). 343 
2. Svitkina, T. The Actin Cytoskeleton and Actin-Based Motility. Cold Spring Harb. Perspect. Biol. 344 
10, 1–22 (2018). 345 
3. Robertson, S. P. Filamin A: Phenotypic diversity. Curr. Opin. Genet. Dev. 15, 301–307 (2005). 346 
4. Sjöblom, B., Ylänne, J. & Djinović-Carugo, K. Novel structural insights into F-actin-binding and 347 
novel functions of calponin homology domains. Curr. Opin. Struct. Biol. 18, 702–708 (2008). 348 
5. Gimona, M., Djinovic-Carugo, K., Kranewitter, W. J. & Winder, S. J. Functional plasticity of CH 349 
domains. FEBS Lett. 513, 98–106 (2002). 350 
6. Ruskamo, S. & Ylänne, J. Structure of the human filamin A actin-binding domain. Acta 351 
Crystallogr. Sect. D Biol. Crystallogr. 65, 1217–1221 (2009). 352 
7. Clark, A. R., Sawyer, G. M., Robertson, S. P. & Sutherland-Smith, A. J. Skeletal dysplasias due to 353 
filamin A mutations result from a gain-of-function mechanism distinct from allelic neurological 354 
disorders. Hum. Mol. Genet. 18, 4791–4800 (2009). 355 
8. Bresnick, A. R., Warren, V. & Condeelis, J. Identification of a Short Sequence Essential for Actin 356 
Binding by Dictyostelium ABP-120. J. Biol. Chem. 265, 9236–9240 (1990). 357 
9. Levine, B. A., Moir, A. J. G., Patchell, V. B. & Perry, S. V. The interaction of actin with 358 
dystrophin. FEBS Lett. 263, 159–162 (1990). 359 
10. Karinch, A. M., Zimmer, W. E. & Goodman, S. R. The identification and sequence of the actin-360 
binding domain of human red blood cell beta spectrin. J. Biol. Chem. 265, 11833–11840 (1990). 361 
11. Levine, B., Moir, A., Patchell, V. & Perry, S. Binding sites involved in the interaction of actin 362 
with the N-terminal region of dystrophin. FEBS Lett. 298, (1992). 363 
12. Hemmings, L., Kuhlman, P. A. & Critchley, D. R. Analysis of the actin-binding domain of alpha-364 
actinin by mutagenesis and demonstration that dystrophin contains a functionally homologous 365 
domain. J. Cell Biol. 116, 1369–1380 (1992). 366 
17 
 
13. Corrado, K., Mills, P. & Chamberlain, J. Deletion analysis of the dystrophin-actin binding domain. 367 
FEBS Lett. 344, 255–260 (1994). 368 
14. Goldsmith, S. C. et al. The structure of an actin-crosslinking domain from human fimbrin. Nat. 369 
Struct. Biol. 4, 708–712 (1997). 370 
15. Keep, N. H. et al. Crystal structure of the actin-binding region of utrophin reveals a head-to-tail 371 
dimer. Structure 7, 1539–1546 (1999). 372 
16. Norwood, F. L. M., Sutherland-Smith, A. J., Keep, N. H. & Kendrick-Jones, J. The structure of the 373 
N-terminal actin-binding domain of human dystrophin and how mutations in this domain may 374 
cause Duchenne or Becker muscular dystrophy. Structure 8, 481–491 (2000). 375 
17. Liu, J., Taylor, D. W. & Taylor, K. A. A 3-D reconstruction of smooth muscle α-actinin by 376 
CryoEm reveals two different conformations at the actin-binding region. J. Mol. Biol. 338, 115–377 
125 (2004). 378 
18. Galkin, V. E., Orlova, A., Cherepanova, O., Lebart, M.-C. & Egelman, E. H. High-resolution 379 
cryo-EM structure of the F-actin-fimbrin/plastin ABD2 complex. Proc. Natl. Acad. Sci. U. S. A. 380 
105, 1494–1498 (2008). 381 
19. Galkin, V. E., Orlova, A., Salmazo, A., Djinovic-Carugo, K. & Egelman, E. H. Opening of tandem 382 
calponin homology domains regulates their affinity for F-actin. Nat. Struct. Mol. Biol. 17, 614–6 383 
(2010). 384 
20. Lin, A. Y., Prochniewicz, E., James, Z. M., Svensson, B. & Thomas, D. D. Large-scale opening of 385 
utrophin’s tandem calponin homology (CH) domains upon actin binding by an induced-fit 386 
mechanism. Proc. Natl. Acad. Sci. U. S. A. 108, 12729–33 (2011). 387 
21. Broderick, M. J. F., Bobkov, A. & Winder, S. J. Utrophin ABD binds to F-actin in an open 388 
conformation. FEBS Open Bio 2, 6–11 (2012). 389 
22. Avery, A. W. et al. Structural basis for high-affinity actin binding revealed by a beta-III-spectrin 390 
SCA5 missense mutation. Nat. Commun. 8, 1–7 (2017). 391 
23. Nakamura, F., Osborn, T. M., Hartemink, C. a., Hartwig, J. H. & Stossel, T. P. Structural basis of 392 
18 
 
filamin A functions. J. Cell Biol. 179, 1011–1025 (2007). 393 
24. Razinia, Z., Mäkelä, T., Ylänne, J. & Calderwood, D. A. Filamins in Mechanosensing and 394 
Signaling. Annu. Rev. Biophys. 41, 227–246 (2012). 395 
25. Nakamura, F., Stossel, T. P. & Hartwig, J. H. The filamins: Organizers of cell structure and 396 
function. Cell Adhes. Migr. 5, 160–169 (2011). 397 
26. Sheen, V. L. et al. Mutations in the X-linked filamin 1 gene cause periventricular nodular 398 
heterotopia in males as well as in females. Hum. Mol. Genet. 10, 1775–83 (2001). 399 
27. Parrini, E. et al. Periventricular heterotopia : phenotypic heterogeneity and correlation with 400 
Filamin A mutations. Brain 72, 1892–1906 (2006). 401 
28. Chen, M. H. et al. Thoracic aortic aneurysm in patients with loss of function Filamin A mutations: 402 
Clinical characterization, genetics, and recommendations. Am. J. Med. Genet. 176A, 337–350 403 
(2018). 404 
29. Solé, G. et al. Bilateral periventricular nodular heterotopia in France: Frequency of mutations in 405 
FLNA, phenotypic heterogeneity and spectrum of mutations. J. Neurol. Neurosurg. Psychiatry 80, 406 
1394–1398 (2009). 407 
30. Robertson, S. P. Otopalatodigital syndrome spectrum disorders: otopalatodigital syndrome types 1 408 
and 2, frontometaphyseal dysplasia and Melnick-Needles syndrome. Eur. J. Hum. Genet. EJHG 409 
15, 3–9 (2007). 410 
31. Robertson, S. P. et al. Localized mutations in the gene encoding the cytoskeletal protein filamin A 411 
cause diverse malformations in humans. Nat. Genet. 33, 487–491 (2003). 412 
32. Mentes, A. et al. High-resolution cryo-EM structures of actin-bound myosin states reveal the 413 
mechanism of myosin force sensing. PNAS 115, 1292–1297 (2018). 414 
33. Razinia, Z., Baldassarre, M., Cantelli, G. & Calderwood, D. A. ASB2α, an E3 ubiquitin ligase 415 
specificity subunit, regulates cell spreading and triggers proteasomal degradation of filamins by 416 
targeting the filamin calponin homology 1 domain. J. Biol. Chem. 288, 32093–32105 (2013). 417 
34. Singh, S. M., Bandi, S. & Mallela, K. M. G. The N‑Terminal Flanking Region Modulates the 418 
19 
 
Actin Binding Affinity of the Utrophin Tandem Calponin-Homology Domain. Biochemistry 56, 419 
2627–2636 (2017). 420 
35. Weins, A. et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its 421 
F-actin-binding affinity. Proc. Natl. Acad. Sci. U. S. A. 104, 16080–16085 (2007). 422 
36. Valdés-Mas, R. et al. Mutations in filamin C cause a new form of familial hypertrophic 423 
cardiomyopathy. Nat. Commun. 5, 5326 (2014). 424 
37. Bagnall, R. D., Molloy, L. K., Kalman, J. M. & Semsarian, C. Exome sequencing identifies a 425 
mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular 426 
noncompaction, and sudden death. BMC Med. Genet. 15, 99 (2014). 427 
38. Kunishima, S. et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am. J. Hum. 428 
Genet. 92, 431–438 (2013). 429 
39. Theis, J. L. et al. Echocardiographic-determined septal morphology in Z-disc hypertrophic 430 
cardiomyopathy. Biochem. Biophys. Res. Commun. 351, 896–902 (2006). 431 
40. Jenkins, Z. A. et al. Differential regulation of two FLNA transcripts explains some of the 432 
phenotypic heterogeneity in the loss-of-function filaminopathies. Hum. Mutat. 39, 103–113 433 
(2018). 434 
41. Sawyer, G. M., Clark, A. R., Robertson, S. P. & Sutherland-Smith, A. J. Disease-associated 435 
Substitutions in the Filamin B Actin Binding Domain Confer Enhanced Actin Binding Affinity in 436 
the Absence of Major Structural Disturbance: Insights from the Crystal Structures of Filamin B 437 
Actin Binding Domains. J. Mol. Biol. 390, 1030–1047 (2009). 438 
42. Kostan, J., Gregor, M., Walko, G. & Wiche, G. Plectin isoform-dependent regulation of keratin-439 
integrin α6β4 anchorage via Ca2+/calmodulin. J. Biol. Chem. 284, 18525–18536 (2009). 440 
43. Song, J. G. et al. Structural insights into Ca2+-calmodulin regulation of plectin 1a-integrin β4 441 
interaction in hemidesmosomes. Structure 23, 558–570 (2015). 442 
44. Nakamura, F., Hartwig, J. H., Stossel, T. P. & Szymanski, P. T. Ca2+ and Calmodulin Regulate 443 
the Binding of Filamin A to Actin Filaments. J. Biol. Chem. 280, 32426–32433 (2005). 444 
20 
 
45. García-Alvarez, B., Bobkov, A., Sonnenberg, A. & De Pereda, J. M. Structural and functional 445 
analysis of the actin binding domain of plectin suggests alternative mechanisms for binding to F-446 
actin and integrin β4. Structure 11, 615–625 (2003). 447 
 448 
Figure Legends 449 
 450 
Figure 1. Cryo-EM map and model of FLNaABD-E254K bound to F-actin. a The cryo-EM 451 
map (left and middle) has been filtered to 3.6 Å resolution, masked to illustrate the actin and 452 
FLNaCH1 region, and fit with computationally refined models (right) for actin (different subunits 453 
in dark blue, cyan, and light blue) and the FLNaCH1 domain (green). Phalloidin (orange) and 454 
Mg.ADP (grey) were resolved within F-actin. b The binding interface of the FLNaABD (green 455 
ribbon) consists of the N-terminal actin-binding site ABS-N (pink), actin-binding site 2 (ABS2, 456 
yellow) and the ABS2 extension (ABS2’, red), which makes contacts with actin subunits (n) (dark 457 
blue, surface representation) and (n+2) (light blue, surface representation) on actin subdomains 1 458 
and 2 (SD1 and SD2, labeled in grey).  459 
 460 
Figure 2. ABS-N contributes to F-actin binding. a Cryo-EM density depicting ABS-N (residues 461 
P29-K43, pink) extending from helix-A of the FLNaCH1 domain (green) alongside actin(n) (dark 462 
blue). b Superposition of the refined actin-bound FLNaCH1 and ABS-N (green, pink) cryo-EM 463 
structure and the published unbound FLNaCH1 crystal structure PDB 3HOC (red) illustrates the 464 
formation of the structured ABS-N upon actin-binding. Actin in surface representation and FLNa 465 
in ribbon representation, colored as in (a). c F-actin targeting of wild-type (wt) and N-terminal 466 
deletion constructs of FLNaABD-GFP expressed in mouse NIH-3T3 fibroblasts. Bars = mean ± 467 
SEM, n = number of scored cells from 3 independent experiments, * significantly different from 468 
21 
 
wt (P<0.001) in a one-way ANOVA (F6,944=211) with Dunnett’s multiple comparisons test. d 469 
Pearson’s correlation coefficient (PCC) scoring of FLNaABD-GFP co-localization with N-470 
terminal truncations. Center = median, boxes = 25th-50th and 50th-75th percentiles, whiskers extend 471 
to 10th and 90th percentiles, n = number of scored cells from 3 independent experiments, * 472 
significantly different from wt (P<0.001) in a one-way ANOVA (F6,711=21.63) with Dunnett’s 473 
multiple comparisons test. e Detailed view of actin-binding by ABS-N with binding residues in 474 
stick representation. f Cryo-EM density supports a probable cation-π interaction between FLNa 475 
W41 and actin R28. g F-actin targeting of ABS-N-mutant FLNaABD-GFP, scored and graphed as 476 
in (c). One-way ANOVA (F3,564=339.9) with Dunnett’s multiple comparisons test. h PCC scoring 477 
of ABS-N-mutant FLNaABD-GFP, scored and graphed as in (d). One-way ANOVA (F3,410=13) 478 
with Dunnett’s multiple comparisons test.  479 
 480 
Figure 3. ABS2 and ABS2’ facilitate major binding interactions with F-actin. a Detailed view 481 
of the FLNa ABS2’ (green) binding interface with the actin(n+2) subunit (light blue) and actin(n) 482 
(dark blue). b F-actin targeting scores of ABS2’-mutant FLNaABD-GFP. Bars = mean ± SEM, n 483 
= number of scored cells from 3 independent experiments, * significantly different from wt 484 
(P<0.001) in a one-way ANOVA (F4,670=286.6) with Dunnett’s multiple comparisons test. c PCC 485 
scoring of ABS2’-mutant FLNaABD-GFP. Center = median, boxes = 25th-50th and 50th-75th 486 
percentiles, whiskers extend to 10th and 90th percentiles, n = number of scored cells from 3 487 
independent experiments, * significantly different from wt (P<0.001 unless otherwise specified) 488 
in a one-way ANOVA (F4,585=11.41) with Dunnett’s multiple comparisons test. d Detailed view 489 
of the FLNa ABS2 (green) binding interface with the actin(n+2) subunit (light blue) and actin(n) 490 
(dark blue). e F-actin targeting scores of ABS2-mutant FLNaABD-GFP, scored and graphed as in 491 
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(b). n=number of scored cells from at least 3 independent experiments, one-way ANOVA 492 
(F3,568=308.5) with Dunnett’s multiple comparisons test. f PCC scoring of ABS2-mutant 493 
FLNaABD-GFP, scored and graphed as in (c). n=number of scored cells from at least 3 494 
independent experiments, one-way ANOVA (F3,491=16.75) with Dunnett’s multiple comparisons 495 
test.  496 
 497 
Figure 4. Opening of the ABD is required to avoid steric clashes and facilitate actin binding. 498 
a Low-pass filtered (10 Å resolution) map of FLNaABD-E254K bound to F-actin. FLNaCH2 from 499 
the FLNaABD crystal structure (PDB 3HOC) was independently rigid-body docked into additional 500 
density (tan, right). b, c The FLNaABD crystal structure is superimposed onto the actin-bound 501 
cryo-EM structure to align CH1 domains. Instances of steric clash between the crystallographic 502 
CH2 domain (purple) and F-actin cryo-EM density are indicated by red arrows (b). Repositioning 503 
of the CH2 domain from the closed crystalized form (purple) into its open actin-bound form (tan) 504 
is depicted with an arrow (c). d Actin-targeting scores of FLNa-ABD, -CH1, or -CH2-GFP with 505 
OPDSD mutations. Bars = mean ± SEM, n = number of scored cells from at least 3 independent 506 
experiments, * significantly different from wt (P<0.001) in a one-way ANOVA (F7,1576=1894) 507 
with Dunnett’s multiple comparisons test. e PCC scoring of FLNa-ABD, -CH1, or -CH2-GFP with 508 
OPDSD mutations. Center = median, boxes = 25th-50th and 50th-75th percentile, whiskers extend 509 
to 10th and 90th percentiles, n = number of scored cells from 3 independent experiments, * 510 
significantly different from wt (P<0.001) in a one-way ANOVA (F7,1283=258.7) with Dunnett’s 511 
multiple comparisons test. 512 
 513 
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Figure 5. ABD opening is mediated by an inter-CH domain latch. a FLNaABD crystal 514 
structure showing the W142-H255 cation-π interaction that may latch the CH1 (red) and CH2 515 
(purple) domains closed. b Actin-bound FLNaCH1 (green) reveals W142 interaction with actin 516 
(dark blue). In the closed CH2 conformation (purple) H255 would clash with actin. c F-actin 517 
targeting score of the W142A mutant FLNaABD-GFP. Bars = mean ± SEM, n = number of scored 518 
cells from 4 independent experiments, * significantly different from wt (P<0.001) in a one-way 519 
ANOVA (F2,529=757) with Dunnett’s multiple comparisons test. d PCC scoring of the W142A-520 
mutant FLNaABD-GFP. Center = median, boxes = 25th-50th and 50th-75th percentile, whiskers 521 
extend to 10th and 90th percentiles, n = number of scored cells from 4 independent experiments, * 522 
significantly different from wt (P<0.001) in a one-way ANOVA (F2,424=28.1) with Dunnett’s 523 
multiple comparisons test. e Triplicate derivative melting curves from differential scanning 524 
fluorimetry for purified wt, Q170P, and E254K FLNaABDs indicate a single melting temperature 525 
peak for each protein: wt = 48.1 ± 0.6 °C, Q170P = 40.1 ± 0.8 °C, E254K = 39.3 ± 0.5 °C (± SD). 526 
f Left, representative Coomassie-stained actin co-sedimentation assay gels containing pellet (top) 527 
or supernatant (bottom) samples with no-actin controls (middle) for purified wt, Q170P, and 528 
E254K FLNaABDs. Uncropped gel images are shown in Supplementary Data Set 1. On the right, 529 
assay data points were plotted to generate a binding curve to calculate an apparent dissociation 530 
constant (Kd). g Apparent Kd was averaged for each ABD from at least six co-sedimentation 531 
assays. Bars = mean ± SEM, n = number of independent co-sedimentation assays, * significantly 532 
different from wt in an unpaired two-tailed t-test (wt vs. Q170P, t=2.501, df=14, P=0.0254; wt vs. 533 
E254K, t=4.086, df=14, P=0.0011) (see also Supplementary Fig. 4d). 534 
 535 
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Figure 6. FLNaCH1 domain mutations confer a loss-of-function to F-actin binding. a F-actin 536 
targeting scores of periventricular nodular heterotopia disease mutant FLNaABD-GFP. Bars = 537 
mean ± SEM, n=number of scored cells from at least 3 independent experiments, n = number of 538 
scored cells from at least 3 independent experiments, * significantly different from wt (P<0.001)  539 
in a one-way ANOVA (F9,1680=227.5) with Dunnett’s multiple comparisons test. b PCC scoring 540 
of periventricular nodular heterotopia disease mutant FLNaABD-GFP. Center = median, boxes = 541 
25th-50th and 50th-75th percentile, whiskers extend to 10th and 90th percentiles, n = number of scored 542 
cells from at least 3 independent experiments, * significantly different from wt (P<0.001) in a one-543 
way ANOVA (F9,1234=27.64) with Dunnett’s multiple comparisons test. c Left, representative 544 
Coomassie-stained actin co-sedimentation assay gels containing pellet (top) or supernatant 545 
(bottom) samples with no-actin controls (middle) for purified wt, A39G, and A128V FLNaABDs. 546 
Uncropped gel images are shown in Supplementary Data Set 1. On the right, assay data points 547 
were plotted to generate a binding curve to calculate an apparent dissociation constant (Kd). d 548 
Apparent Kd was averaged for FLNaABD-wt, -A39G, or -A128V protein from at least four assays 549 
(wt here is the same as appears in Fig. 5g for comparison purposes). Bars = Mean ± SEM, n = 550 
number of independent co-sedimentation assays, * significantly different from wt in an unpaired 551 
two-tailed t-test (wt vs. A39G, t=4.163, df=13, P=0.0011; wt vs. A128V, t=5.934, df=12, 552 
P<0.0001) (see also Supplementary Fig. 4d). e Triplicate derivative melting curves from 553 
differential scanning fluorimetry for purified wt, A39G, and A128V FLNaABDs indicate a single 554 
melting temperature peak for each protein (wt here is the same as appears in Fig. 5e for comparison 555 
purposes): wt = 48.1 ± 0.6 °C, A39G = 47.3 ± 0.5 °C, A128V = 42.0 ± 0.9 °C (± SD).   556 
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Table 1. Cryo-EM data collection, refinement and validation statistics 557 
 Krios- 
ABD-E254K 
(EMDB-7831,  
PDB 6D8C) 
F20- 
ABD-E254K 
(EMDB-8918) 
F20- 
ABD-Q170P 
(EMDB-7832) 
F20- 
ABD-wt 
(EMDB-7833) 
Data collection and processing     
Magnification 37500 40096 40096 40096 
Voltage (kV) 300 200 200 200 
Electron exposure (e–/Å2) 51 46-53 60 47 
Defocus range (μm) 1.0 – 2.9 1.1 – 2.7 1.1 – 2.7  1.1 – 2.7 
Pixel size (Å) 1.33 1.247 1.247 1.247 
Symmetry imposed 27.54 Å rise 
-166.73˚ twist 
27.67 Å rise 
-166.89˚ twist 
27.52 Å rise 
-166.88˚ twist 
None 
Initial particle images (no.) ~450,000 28,000 20,000 75,000 
Final particle images (no.) 67,000 28,000 20,000 24,000 
Map resolution (Å) 3.54 7.4 6.6 9.8 
    FSC threshold 0.143 0.143 0.143 0.143 
Map resolution range (Å) 3.3 – 5.2 5.1 – 8.6 5.3 – 7.8 6.2 – 10.2 
     
Refinement     
Initial model used (PDB code) 3HOC, 6C1D 
ChEBI:8040 
   
Model resolution (Å) 3.76    
    FSC threshold 0.500    
Model resolution range (Å) 3.76 – 45    
Map sharpening B factor (Å2) -150    
Model composition     
    Nonhydrogen atoms 19665    
    Protein residues 2455    
    Ligands 5 Mg.ADP, 
3 phalloidin 
   
B factors (Å2)     
    Protein 49.91    
    Ligand 42.24    
R.m.s. deviations     
    Bond lengths (Å) 0.005    
    Bond angles (°) 1.071    
     
Validation     
MolProbity score 1.65    
Clashscore 9.19    
Poor rotamers (%) 0.71    
Ramachandran plot     
    Favored (%) 97.08    
    Allowed (%) 2.92    
    Disallowed (%) 0    
 558 
 559 
 560 
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Online Methods 561 
 562 
Reagents and DNA constructs 563 
Polyclonal anti-GFP (#600-101-215, Rockland), anti-vinculin (V9131, Sigma-Aldrich), secondary 564 
anti-goat-680RD (#926-68074, LI-COR), secondary anti-mouse 800CW (#925-32212, LI-COR), 565 
and Alexafluor-568-phalloidin (Life Technologies) were purchased. Polyclonal anti-human FLNa 566 
antibody, which cross-reacts with mouse FLNa, was raised in rabbits46,47. 1 mg/ml fibronectin 567 
solution was purchased (#F1141, Sigma). Human FLNa-ABD and -CH domain constructs in a 568 
pcDNA3 vector with a C-terminal GFP tag have been described previously33,48,49. FLNa mutations 569 
were generated by QuikChange site-directed mutagenesis (Stratagene). For bacterial expression, 570 
select FLNa-ABD constructs were also subcloned into a modified pET32-6xHis vector using KpnI 571 
and EcoRI restriction sites to generate N-terminally His-tagged FLNaABD. 572 
 573 
Cell culture 574 
Mouse NIH3T3 cells were obtained from Yale colleagues and tested negative for mycoplasma 575 
contamination. Cells were cultured in DMEM (#11965, GIBCO) with 9% bovine serum 576 
(#16170078, GIBCO) and penicillin/streptomycin (#15140122, GIBCO), and incubated at 37 °C 577 
in a humidified atmosphere containing 5% CO2. To express FLNa constructs, 8 × 104 cells/well 578 
were plated in a 6-well dish and 24 h later were transfected with 1.5 µg plasmid DNA using PEI 579 
(#23966-1, Polysciences Inc).  580 
 581 
Actin Filament Targeting and Microscopy  582 
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Transfected cells were plated on coverslips previously coated with 5 µg/mL fibronectin and 583 
cultured for 24 h. Cells were washed with PBS and then fixed and permeabilized in cold 4% 584 
paraformaldehyde + 0.1% Triton X-100 in cytoskeletal buffer (10 mM MES, pH6.1, 150 mM 585 
NaCl, 5 mM EGTA, 5 mM MgCl2, 5 mM glucose) for 30 min at room temperature. Coverslips 586 
were washed with PBS and incubated in cytoskeletal buffer containing 0.2% bovine serum 587 
albumin (BSA), 50 mM NH4Cl, and 0.3% Triton X-100 for 1 h at room temperature, then 588 
incubated for 1 h at room temperature with Alexafluor-568-Phalloidin in the same buffer and 589 
washed in PBS. Coverslips were mounted onto glass slides using ProLong Diamond Antifade 590 
Mountant (#P36965, Invitrogen). Microscopy images of transfected cells expressing comparable 591 
levels of GFP were acquired using a Nikon Eclipse Ti microscope with a 100x objective using 592 
Micro-Manager software50 and analyzed in ImageJ (National Institutes of Health, Bethesda, 593 
rsb.info.nih.gov). To quantify GFP-tagged FLNaABD targeting to actin filaments, co-localization 594 
of GFP and phalloidin-568 signal was scored on a scale of 1 (low overlap) to 7 (high overlap) in a 595 
sample-blind manner. To avoid potential bias in assigning co-localization scores, GFP and 596 
phalloidin-568 signal images were also subjected to an automated CellProfiler co-localization 597 
function51 to normalize images and calculate the Pearson’s Correlation Coefficient (PCC) between 598 
the two images. Images were excluded from automated PCC scoring if the field contained non-599 
expressing or multiple cells. In all cases the expression of the GFP-tagged FLNa construct at the 600 
predicted molecular weight was confirmed by immunoblotting against GFP, while vinculin was 601 
used as a loading control.  602 
 603 
Protein Purification 604 
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6xHis-tagged FLNaABD DNA constructs were expressed in Rosetta strain E. coli and induced 605 
with 500 µM IPTG for 18 h at 16 °C. Bacterial cultures were pelleted and resuspended in lysis 606 
buffer (20 mM Tris pH 7.9, 500 mM NaCl, 5 mM imidazole, 1 mM PMSF, 1% Triton X-100, 700 607 
µg/mL Lysozyme, 6.4 µg/mL DNAse1) at 4 °C. 6xHis-tagged proteins were purified over Ni-NTA 608 
beads (#70666 Novagen), eluted with 400 mM imidazole, and dialyzed into co-sedimentation 609 
assay buffer (50 mM Tris pH 8.0, 150 mM KCl, 2 mM MgCl2, 0.01% Triton X-100, 5 mM DTT). 610 
Proteins were further purified by size-exclusion chromatography (SEC) on a Superdex200 Prep 611 
Grade column (GE Healthcare), then concentrated using a 10 kDa MWCO centrifugal filter unit 612 
(#UFC801024, Millipore), flash frozen in liquid nitrogen, and stored at -80 °C until use. Purified 613 
proteins remained monomeric after concentration and freezing as seen in SEC (data not shown).  614 
 615 
Actin Co-sedimentation Assays 616 
Actin, purified from chicken breast into G buffer (2 mM Tris pH8, 200 µM ATP, 5 mM DTT, 100 617 
µM CaCl2) and stored at -80 °C until use, was a gift from the Koleske lab (Yale)52. 1 µM G-actin 618 
was polymerized with 20 mM imidazole, 150 mM KCl, 2 mM EGTA, 4 mM DTT, and 2 mM 619 
MgCl2 for 30 min at room temperature and stabilized with 1 µM phalloidin. Polymerized actin 620 
was titrated with a range of FLNaABD concentrations in co-sedimentation assay buffer, incubated 621 
at room temperature for 1 h, and spun at 270,000 × g in a Beckman TLA-100 rotor. Supernatants 622 
were collected, and protein pellets were washed with co-sedimentation assay buffer then 623 
resuspended in water. 30% of the supernatant sample and 100% of the pellet sample were loaded 624 
for SDS-PAGE separation. Gels were stained with Coomassie Blue, destained, and scanned for 625 
densitometry using the Odyssey Infrared Imaging system (LI-COR). No-actin control ABD band 626 
intensities were subtracted from the corresponding co-sedimented ABD bands to remove F-actin-627 
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independent sedimentation signal and divided by the intensity of the actin to normalize for F-actin 628 
loading. Data points were fitted to a one-site binding model in Prism software (GraphPad) to 629 
calculate apparent binding affinity and stoichiometry53.  630 
 631 
Differential Scanning Fluorimetry 632 
His-tagged FLNaABD thermal stability was determined by differential scanning fluorimetry with 633 
SYPRO orange54 (#S6650, Invitrogen) using a CFXConnect Real-Time PCR Detection System 634 
(BioRad). 30 µM ABD in co-sedimentation assay buffer was mixed with SYPRO orange and 635 
heated from 4 °C to 95 °C in 1 °C increments over 2 h. Data were collected in triplicate wells using 636 
the FAM filter from three independent experiments. Melting temperatures were calculated from 637 
the first derivative of the melting curve using the BioRad CFX Manager software.  638 
 639 
Cryo-Electron Microscopy Sample Preparation and Data Collection 640 
Purified 6xHis-FLNaABD-wt, -Q170P, or -E254K were incubated at 60 µM with 15 µM 641 
phalloidin-stabilized F-actin in a low salt co-sedimentation assay buffer (described above) at least 642 
30 minutes before freezing. The Q170P and E254K samples were diluted 1:1 in H2O immediately 643 
prior to freezing. Samples were prepared using holey carbon grids (Quantifoil R1.2/1.3 Micro 644 
Tools GmbH, Grosslöbichau, Germany) and a manual plunger device. Micrographs data sets were 645 
collected on a 200-kV FEI Tecnai F20 electron microscope equipped with a Gatan K2 Summit 646 
direct electron-counting camera at a pixel size of 1.247 Å. Micrographs were recorded in 0.3 647 
second sub-frames over 7.2-10.2 seconds for a total dose of 47-60 e-/Å2 over a nominal defocus 648 
range of 1.1–2.7 µm. Later, a separate data set on the E254K sample was collected on a 300-kV 649 
Titan Krios microscope equipped with an energy filter and a Gatan K2 Summit camera in super-650 
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resolution mode at a physical pixel size of 1.33 Å. Micrographs were recorded in 0.25 second sub-651 
frames over 12 seconds for a total dose of 50 e-/Å2 over a nominal defocus range of 1.0–2.9 µm. 652 
 653 
3D Refinement 654 
Micrographs were aligned and dose-corrected using MotionCor255, where sub-frame motion 655 
correction (3x3 array) was applied to the wt and Tecnai F20 E254K data sets, while the Krios 656 
E254K data set was binned by 2. The Krios E254K data set was corrected for magnification 657 
distortion using parameters estimated by mag_distortion_estimate56. Contrast transfer function 658 
parameters were calculated using Gctf57, and micrographs where Gctf did not detect signal at 659 
resolutions better than <4 Å were excluded from structural refinement for the Krios E254K data 660 
set. Filaments were manually selected using e2helixboxer from the EMAN software package58 and 661 
extracted at a spacing of ~27.5 Å. The wt, Q170P, and E254K data sets collected on the Tecnai 662 
F20 used a box size of 390 pixels, while the Krios E254K data set used a box size of 210 pixels. 663 
Structure refinement was performed using IHRSR single-particle helical processing59,60 as 664 
implemented in RELION (version 2.0.3)61,62. The first round of refinement employed masks 665 
generated from earlier refinements that were low-pass filtered to 60 Å and included 10-20 Å soft 666 
edges using the relion_mask_create tool. The Tecnai F20 E254K and Q170P data sets were further 667 
processed in a second round of refinement using a mask generated from the 7 central actin subunits 668 
and CH1 domains that were low-pass filtered to 60 Å and included 15 Å soft edges. The Krios 669 
E254K data set was also improved in a second round of refinement using a helical mask generated 670 
from the results of the first round of refinement but constrained to the central 30% Z-slice, low-671 
pass filtered to 60 Å, and included 6.5 Å soft edges. The wt data was subjected to a particle 672 
subtraction and masked 3D classification approach described elsewhere63 to determine occupancy 673 
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at the single subunit level. The decorated class (~33% particles) was then restored to its 674 
unsubtracted state and further refined using the same mask as earlier in the first round of 675 
refinement. 676 
 677 
The resolution and B-factor of the final maps were calculated from the FSC correlation of 678 
independent half-maps in postprocessing with RELION following gold standard protocols 679 
(Supplementary Fig. 1a). Symmetry was first imposed in real space on the independent half maps 680 
in the Tecnai F20 E254K (27.67 Å rise, -166.89° twist), Q170P (27.52 Å rise, -166.88˚ twist), and 681 
Krios E254K (27.54 Å rise, -166.73˚ twist) data sets using the relion_helix_toolbox command. The 682 
imposed helical parameters were derived from local searches of symmetry on the full map in 683 
RELION. The FSC calculations for the Tecnai F20 E254K and Q170P data sets used a mask 684 
generated from earlier refinements that was thresholded to contain only actin subunits and CH1 685 
domains, low-pass filtered to 20 Å, and included 15 Å soft edges. The resolution of the Tecnai F20 686 
E254K map reach 7.4 Å, while the Q170P map reached 6.6 Å. The symmetrized Krios E254K 687 
volume was used to generate a mask that included only actin and the CH1 domains, was low-pass 688 
filtered to 15 Å, and included 8 Å soft edges. This mask was next used in postprocessing 689 
calculations, where the final Krios E254K map reached a resolution of 3.6 Å. The final 690 
symmetrized Krios E254K map is low-pass filtered to 3.6 Å and sharpened with a B-factor of -691 
150. The FSC calculations for the wt data set used the same mask from its structural refinement, 692 
and reached a resolution of 9.8 Å. The resolution ranges of each map were estimated using blocres 693 
from the Bsoft software package64.  694 
 695 
Model Building, Refinement, and Validation 696 
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PDB models of phalloidin-stabilized F-actin (PDB ID 6C1D, chain B, residues 1-375)32 and FLNa 697 
CH1 (PDB ID 3HOC, chain A, residues 39-153)7 were first fit as rigid bodies into the final 698 
symmetrized Krios E254K map using UCSF Chimera65. This model was refined against the final 699 
map in Phenix66 using real space refinement with simulated annealing. Next, the model was refined 700 
by manual adjustments and all molecule real-space refinement with Ramachandran restraints in 701 
Coot67 and real-space refinement in Phenix without simulated annealing. After several iterations, 702 
additional N-terminal FLNa residues were built by the N-terminal addition of residues into the 703 
cryo-EM density in Coot and followed by real-space refinement in Phenix. Multiple subunits and 704 
phalloidin subunits (PDB ID 6C1D) were loaded into the neighboring densities and evaluated in 705 
MolProbity68 for steric clashes, which were manually fixed in Coot. Next, structural data for 706 
phalloidin (ChEBI ID 8040)69 was used to generate geometric restraints in eLBOW70 for real-space 707 
refinement with the final map in phenix. The refined phalloidin chains were combined with the 708 
model. The final model was evaluated by MolProbity and data statistics are given in Table 1. 709 
Cation-π interactions were investigated using the CaPTURE program71. Structural figures were 710 
generated in ChimeraX72. 711 
 712 
Statistics and Reproducibility 713 
For cellular F-actin co-localization experiments, each GFP-tagged FLNa construct or GFP alone 714 
was tested in at least three independent transfections, with at least 25 image pairs collected for 715 
each construct per experiment for quantification. Actin-targeting scores or PCC scores from 716 
imaged cells for each construct were averaged and compared to FLNaABD-wt by one-way 717 
ANOVA (P<0.0001 for all ANOVAs) with Dunnett’s multiple comparisons test; precise values 718 
for n, F and degrees of freedom are listed in the relevant figures and legends. For co-sedimentation 719 
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assays, each 6xHis-tagged FLNa protein was tested in at least four independent assays, and average 720 
apparent Kd of each mutant FLNaABD was compared to wt with an unpaired two-tailed t-test; 721 
precise values for n, t, P and degrees of freedom are listed in the relevant figures and legends. For 722 
differential scanning fluorimetry, average melting temperature of each mutant FLNaABD was 723 
compared to wt from triplicate wells of three independent experiments by one-way ANOVA 724 
(F4,40=339.1, P<0.0001) with Dunnett’s multiple comparisons test. 725 
 726 
Data availability 727 
Cryo-EM reconstructions were deposited in the Electron Microscopy Data Bank with the 728 
following accession numbers: F20-F-actin-FLNaABD 7833, F20-F-actin-FLNaABD-Q170P 729 
7832, F20-F-actin-FLNaABD-E254K 8918, and Krios-F-actin-FLNaABD-E254K 7831. The 730 
corresponding FLNaABD-E254K filament model was deposited in the Protein Data Bank with 731 
accession number 6D8C. Source data for F-actin targeting analyses (Figs. 2c,d,g,h, 3b,c,e,f, 4d,e, 732 
5c,d, and 6a,b) and co-sedimentation assays (Figs. 5g and 6d) are available with the paper online. 733 
Other data are available from the corresponding author upon reasonable request.  734 
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Supplementary Figure 1.  
FLNaABD-F-actin complexes. 
a High frequency noise-substituted Fourier shell correlation calculations between independently refined half maps reveals the resolution 
of each map. The FSC curve between the final FLNaABD-E254K-F-actin map and refined model is shown in purple. b A 10 Å-filtered 
cryo-EM density map of the wild-type (wt) FLNaABD (left and middle) was rigid-body docked with crystal structures for actin (PDB 
6C1D, different subunits in dark blue, cyan, and light blue) and FLNaCH1 (PDB 3HOP, green) (right). c A 6.6 Å-filtered cryo-EM density 
map of the gain-of-function mutant FLNaABD-Q170P (left and middle) was docked with the refined actin and FLNaCH1 models (right) 
and colored as in (b). d A 7.4 Å-filtered cryo-EM density map of the gain-of-function mutant FLNaABD-E254K (left and middle) was 
docked with the refined actin and FLNaCH1 models (right) and colored as in (b). Observed extra density for FLNaCH2 is shown in tan.  
 
 
 
Supplementary Figure 2 
ABS-N mutations inhibit FLNaABD-F-actin binding. 
a Micrographs of mouse NIH-3T3 fibroblasts transiently transfected with GFP or FLNaABD-GFP ± N-terminal truncation constructs after 
fixation, permeabilization, and staining with Alexafluor-568-phalloidin to visualize F-actin filaments. Cells were imaged in the green (left 
column, GFP Signal) and red (right column, F-actin Signal) channels. Scale bar = 20 µm. wt = wild-type.  b Anti-GFP immunoblot on 
lysates from NIH-3T3 cells transiently transfected with GFP or FLNaABD-GFP ± N-terminal truncations. Vinculin was used as a loading 
control. c Micrographs of fibroblasts transfected with GFP or FLNaABD-GFP constructs containing ABS-N mutations, prepared and 
imaged as in (a). Scale bar = 20 µm. d Anti-GFP immunoblot on lysates from NIH-3T3 cells transiently transfected with GFP or 
FLNaABD-GFP ± ABS-N mutations. Vinculin was used as a loading control. 
 
 
 
Supplementary Figure 3 
Immunoblotting of ABS2’ and ABS2 mutant FLNaABDs. 
a Anti-GFP immunoblot on lysates from NIH-3T3 cells transiently transfected with GFP or FLNaABD-GFP ± ABS2’ mutations. Vinculin 
was used as a loading control. wt = wild-type. b Anti-GFP immunoblot on lysates from NIH-3T3 cells transiently transfected with GFP or 
FLNaABD-GFP ± ABS2 mutations. Vertical separations between panels indicate the exclusion of non-relevant lane samples from the 
same gel. Vinculin was used as a loading control. 
 
 
 
Supplementary Figure 4 
OPDSD-associated mutations increase FLNaABD binding to F-actin. 
a Micrographs of mouse NIH-3T3 fibroblasts transiently transfected with GFP or FLNaABD-GFP ± the Q170P or E254K mutation after 
fixation, permeabilization, and staining with Alexafluor-568-phalloidin to visualize actin filaments. Cells were imaged in the green (left 
column, GFP Signal) and red (right column, F-actin Signal) channels. Scale bar = 20 µm. wt = wild-type. b Top and bottom, anti-GFP 
immunoblots on lysates from NIH-3T3 cells transiently transfected with GFP, FLNaABD-GFP or isolated FLNaCH-GFP domains ± the 
Q170P or E254K mutation. Vinculin was used as a loading control. Vertical separations between panels indicate the exclusion of non-
relevant lane samples from the same gel. c Anti-GFP immunoblot on lysates from NIH-3T3 cells transiently transfected with GFP, 
FLNaABD-GFP or FLNaABD-W142A-GFP. Vinculin was used as a loading control. d Table summarizing apparent dissociation 
constants (Kd, µM) and Bmax (molar ratio ABD:actin) from co-sedimentation assays with purified wt or mutant 6x-His-FLNaABD 
proteins, ± standard deviation. 
 
 
 
Supplementary Figure 5 
Immunoblotting and size-exclusion chromatography of FLNaABD with PVNH-associated mutations. 
a Top and bottom, anti-GFP immunoblots on lysates from NIH-3T3 cells transiently transfected with GFP or FLNaABD-GFP ± PVNH 
mutations. Vinculin was used as a loading control. wt = wild-type. b Analytical size-exclusion chromatography of purified bacterially 
expressed 6x-His-FLNaABD-wt, -A39G, or -A128V. Protein concentration was measured by UV absorbance at 280 nm (arbitrary units, 
mAU). c Top, the FLNa residue A128 is located in Helix-F of the CH1 domain and does not contact actin, though its mutation to valine 
would likely perturb this short helix (see space-filling models, bottom) which contains important actin-binding residues (not shown) and 
result in a loss of actin binding. d The FLNaCH1 residues E82 and S149 (mutated in PVNH) are situated far from F-actin binding sites 
in the actin-bound cryo-EM structure.  
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Supplementary Note. Protein sequence alignment of selected human ABDs.  
 
ABDs of FLNa (UniProt Accession Code O21333), FLNb (O75369), FLNc (Q14315), α-actinin 1 (ACTN1 P12814), ACTN2 (P35609), 
ACTN3 (Q08043), ACTN4 (O43707), β-III-spectrin (SPTN2 O15020), dystrophin (DMD P11532), utrophin (UTRO P46939) were 
aligned using MultAlin1. F-actin-interacting regions in FLNa are bolded and boxed (red = ABS-N, green = ABS2’, blue = ABS2). 
Secondary structure α-helical elements from FLNa are shown above the alignment as α’s and are labeled with the corresponding CH 
domain and helix letter identifier. The consensus sequence indicates high conservation (>90%, upper-case amino acid code 
abbreviation), low conservation (50-90%, lower-case abbreviation), or molecular group conservation (! = I or V, $ = L or M, % = F or 
Y, # = N, D, Q, or E). Highlighted residues indicate disease-associated point mutations at this position: magenta = PVNH2–11, blue = 
OPDSD12–17, yellow = Larsen syndrome, atelosteogenesis I and III and Boomerang dysplasia disorders18–23, orange = distal and 
cardiomyopathies24–29, grey = macrothrombocytopenia30, maroon = focal segmental glomerulosclerosis31–33, black = spinocerebellar 
ataxia type 534, green = Duchenne’s muscular dystrophy35,36, purple = Becker muscular dystrophy37–41. 
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